
Exclusive: After Covid pivot, biotech nabs funds to be first in the clinic with a non-hormonal contraceptive for men
The goal was to create a non-hormonal contraceptive that women could take to prevent pregnancy and potentially STIs, but the Covid-19 pandemic caused YourChoice Therapeutics to change course and eventually focus most efforts on a non-hormonal pill for men.
With Series A funding and a pre-IND meeting with the FDA under its belt, the biotech expects to be the first company to enter the clinic with an investigational non-hormonal contraceptive for sperm-producers, with the goal of limiting sperm counts to infertile levels. A healthy volunteer study in the US, if greenlit by the agency, will begin in the first half of next year, CEO Akash Bakshi tells Endpoints News.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.